Sensei Biotherapeutics, Inc.
SNSE
$8.05
-$0.15-1.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.32M | 2.67M | 3.55M | 2.13M | 3.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.85M | 5.21M | 7.27M | 6.62M | 7.82M |
| Operating Income | -4.85M | -5.21M | -7.27M | -6.62M | -7.82M |
| Income Before Tax | -4.57M | -4.94M | -6.86M | -7.77M | -7.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.57M | -4.94M | -6.86M | -7.77M | -7.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.57M | -4.94M | -6.86M | -7.77M | -7.25M |
| EBIT | -4.85M | -5.21M | -7.27M | -6.62M | -7.82M |
| EBITDA | -4.82M | -5.17M | -7.24M | -6.29M | -7.49M |
| EPS Basic | -3.62 | -3.91 | -5.45 | -6.17 | -5.77 |
| Normalized Basic EPS | -2.26 | -2.43 | -3.54 | -3.21 | -3.61 |
| EPS Diluted | -3.62 | -3.91 | -5.45 | -6.17 | -5.77 |
| Normalized Diluted EPS | -2.26 | -2.43 | -3.54 | -3.21 | -3.61 |
| Average Basic Shares Outstanding | 1.26M | 1.26M | 1.26M | 1.26M | 1.26M |
| Average Diluted Shares Outstanding | 1.26M | 1.26M | 1.26M | 1.26M | 1.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |